» Articles » PMID: 17192921

Androgens and Androgen Receptors: a Clinically Neglected Sector in Breast Cancer Biology

Overview
Journal J Surg Oncol
Date 2006 Dec 29
PMID 17192921
Citations 9
Authors
Affiliations
Soon will be listed here.
Citing Articles

Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide.

Xia X, Huang C, Liao Y, Liu Y, He J, Guo Z J Exp Clin Cancer Res. 2019; 38(1):220.

PMID: 31126320 PMC: 6534920. DOI: 10.1186/s13046-019-1227-7.


The Apocrine Profile of Triple-negative Breast Carcinomas in Patients Aged 45 Years or Younger: favorable but rare features.

Masili-Oku S, Bacchi C, Fernandes F, Filassi J, Baracat E, Carvalho F Rev Bras Ginecol Obstet. 2016; 38(10):512-517.

PMID: 27813039 PMC: 10309373. DOI: 10.1055/s-0036-1593854.


Expression of Androgen Receptor in Estrogen Receptor-positive Breast Cancer.

Agrawal A, Ziolkowski P, Grzebieniak Z, Jelen M, Bobinski P, Agrawal S Appl Immunohistochem Mol Morphol. 2015; 24(8):550-5.

PMID: 26230371 PMC: 5010278. DOI: 10.1097/PAI.0000000000000234.


Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines.

Rizza P, Barone I, Zito D, Giordano F, Lanzino M, De Amicis F Breast Cancer Res. 2014; 16(1):R21.

PMID: 24552459 PMC: 3978907. DOI: 10.1186/bcr3619.


Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.

Gasparini P, Fassan M, Cascione L, Guler G, Balci S, Irkkan C PLoS One. 2014; 9(2):e88525.

PMID: 24505496 PMC: 3914993. DOI: 10.1371/journal.pone.0088525.